SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?


To: BigKNY3 who wrote (485)2/1/1998 5:04:00 PM
From: Tunica Albuginea  Read Replies (1) | Respond to of 9523
 
BigKNY3," Doctors raving about Viagra ". Can you post those sources for us to see? The only one I have is from Tom Lue, MD , a principal
Viagra investigator, who last year in a Barrons' letter commentary on Vivus, he was asked "if he is buying PFE " and " he smiled and said no, it is too expensive "; at that time PFE was perhaps 25% less than
it is now ! I don't see any raves. The Urologists that I hear all tell me " it is 'supposed' to work well when it comes out, but
'I really don't know much more about it' ".
So the situation we have here so far as far as I am concerned are what we physicians call " soft data": soft data are defined as
- abstracts at the Amer Urolo Meeeting ( 1/4 page ).
-2nd class publications such as The Brit Jour of Urol ( 1 Viagra
article) and the Internat Jour of Impotence ( 1 article ). The
reason they are considered 2nd class is because it is easy to
publish articles in them; only mild scrutiny; The New England Jour
of Medicine ( it's editorial board residing at Harvard Medical
School), which published the Vivus study, would have rejected the
above two Viagra studies for many reasons.
Again it behooves investors to learn about the AVAILABLE EVIDENCE
before investing in dreams. A good place to start is with all the facts. I include the following for a start.

Message 3309509

Anxiously awaiting " hard data" on Viagra.Thanx for your posting any, TA